SecBot SecBot

ELOX

Eloxx Pharmaceuticals, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001035354 Biotech & Drug Discovery
$13.16 +0.36 (+2.81%)
Oct 26 4:00 PM ET · prev $12.80
Market cap
$53.0M
Micro cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$39.00
+196% · range $32.00–43.00
Since first trade
+19.5%
from $11.01 · Jun 9
30 days
−12.3%
from $15.00
Range since listing
$10.95–20.98
−37% from high · low Jul 7
Avg volume 20D
22.6K
Oct 16 spike 66.5K
Short interest
53.9K
≈1.3% of shares · +18.2%
Days to cover
2.4
at average volume
Insider net
$0
no open-market trades · 12 mo
Filing reports
8
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/3
Strongest NEUTRAL Eloxx Pharmaceuticals appointed Geno J. Germano to its board (expanding from five to six directors) and…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • Short sellersBUILDING

    Short interest +18.2% to 53.9K shares. 2.4 days to cover, ≈1.3% of shares.

  • TrendDOWNTREND

    16% below its 50-day average.

Who's buying

13F
Top holderSharesValue
Aberdeen Group plc400,000$5.6M
VANGUARD CAPITAL MANAGEMENT LLC78,680$1.1M
VANGUARD FIDUCIARY TRUST CO10,602$147.2K
MORGAN STANLEY1,544$21.4K
Vanguard Global Advisers, LLC718$10.0K
UBS Group AG637$8.8K
WELLS FARGO & COMPANY/MN126$1.7K
ROYAL BANK OF CANADA98$1.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy4Buy5Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +196%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 15, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
Sep 18, 2026Leerink Partners
INITIATE
INITIATEOutperform
Aug 24, 2026Guggenheim
REITERATE
REITERATEBuy
Aug 20, 2026LUCID CAPITAL MARKETS
INITIATE
INITIATEBuy
Jul 22, 2026LifeSci Capital
INITIATE
INITIATEOutperform
Jul 20, 2026Guggenheim
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 19, 2026
Germano Geno J
Director
AWARD13,587 sh
Jun 10, 2026
Aggarwal Sumit
President and CEO
AWARD328,833 sh
Jun 10, 2026
Domicilium Real Estate Fund III LP
10%+ Owner
OTHER238,422 sh
Jun 10, 2026
Domicilium Real Estate Fund III LP
10%+ Owner
OTHER238,422 sh
Jun 10, 2026
Domicilium Real Estate Fund III LP
10%+ Owner
OTHER361,578 sh
Jun 10, 2026
Domicilium Real Estate Fund III LP
10%+ Owner
OTHER361,578 sh
Jun 8, 2026
Walts Alan Edmund
Director
AWARD8,590 sh
Jun 8, 2026
Rubin Steven D
Director
AWARD4,018 sh

Earnings setup

Estimates
−$0.58
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.58-$0.65–-$0.51+5.5%$0.00
Next Q-$0.66-$0.72–-$0.58+5.5%$0.00
Current FY-$2.23-$2.85–-$0.99-6.0%$0.00
Next FY-$2.55-$3.61–-$1.83+6.5%$0.00

Short side

FINRA· Sep 30, 2026
53,935
shares short
+18.2%
vs prior settlement
2.4
days to cover
≈1.3%
of shares outstanding
Trading halts
Jul 9, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Eloxx Pharmaceuticals appointed Geno J. Germano to its board (expanding from five to six directors) and announced the…
8-K — Impact 4/10
Oct 19, 2026 Insider
Germano Geno J was granted 13,587 shares
Director
Sep 21, 2026 SEC
Eloxx Pharmaceuticals' S-1 registration statement (File No. 333-298904) became effective on September 18, 2026…
EFFECT — Impact 5/10
Sep 11, 2026 SEC
Eloxx Pharmaceuticals filed an S-1 registration statement for the resale of 600,000 shares of common stock and up to…
S-1 — Impact 4/10
Sep 11, 2026 Other
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
First two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled
Jun 10, 2026 Insider
Aggarwal Sumit was granted 328,833 shares
President and CEO
Jun 10, 2026 Insider
Domicilium Real Estate Fund III LP acquired 238,422 shares
10%+ Owner
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 11, 2026
Press release
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
First two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final…
Jul 9, 2026
Trading halt
Halt Resumed: ELOX — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-07-09T15:17:56.000Z | Resumed 2026-07-09T15:22:56.000Z
Jul 9, 2026
Trading halt
Trading Halt: ELOX — LUDP (Volatility Trading Pause)
Eloxx Pharmaceuticals Cmn | Market: NASDAQ | Code: LUDP — Volatility Trading Pause

SecBot reports

8 filings · 0 bullish · 0 bearish · 8 neutral
All ELOX filing & press-release reports (8)